Business Context and Reporting Period
Jasper Therapeutics, Inc. filed this Current Report on Form 8-K on June 20, 2023, under Items 5.02, 8.01, and 9.01. The filing concerns changes to the board of directors and does not report quarterly or annual financial results. Jasper is a biotechnology company; the filing identifies its Nasdaq-listed common stock under ticker JSPR and redeemable warrants under ticker JSPRW.
Key Financial Metrics and Capitalization
- The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other operating financial metrics.
- The filing does not provide updated share counts, valuation data, or warrant activity.
- Dr. Scott Brun received an option to purchase 94,000 shares of voting common stock. The exercise price equals the closing price of the common stock on June 20, 2023, but the filing text does not provide that price.
Material Changes
- Effective June 20, 2023, the board appointed Scott Brun, M.D., as a Class I director.
- Dr. Brun was appointed chair of the Research and Development Committee and a member of the Compensation Committee.
- Lawrence Klein resigned from the board effective June 20, 2023. The company stated that the resignation was not due to any dispute or disagreement regarding the company’s operations, policies, or practices.
- Dr. Brun’s director option vests 25% on the first anniversary of the grant date and 1/48 monthly thereafter, subject to continued service.
- Dr. Brun will receive standard non-employee director cash retainers and entered into the company’s standard director indemnification agreement.
Outlook, Risks, and Unusual Items
- The filing provides no financial guidance, clinical-development outlook, or management forecast.
- Dr. Brun brings prior biopharmaceutical research, development, portfolio management, commercialization, and strategic experience, including senior roles at AbbVie and Abbott Laboratories.
- The filing states that Dr. Brun has no family relationship with any director or executive officer, was not appointed pursuant to an arrangement or understanding, and has no reportable related-party transaction under Item 404(a) of Regulation S-K.
- The option grant and associated director compensation will increase equity-based compensation and potential share dilution, although the filing does not quantify the accounting expense or dilution impact.
Important Facts to Verify
- Verify the closing share price on June 20, 2023, which establishes the exercise price of Dr. Brun’s 94,000-share option.
- Review Jasper’s latest Form 10-Q or Form 10-K for cash runway, liquidity, debt, operating losses, research expenses, and share count.
- Confirm the final board and committee composition following Mr. Klein’s resignation.
- Review Exhibit 99.1 for any additional statements regarding Dr. Brun’s appointment or the company’s strategic priorities.